Meda said that it markets a higher strength (5%) of imiquimod in Europe under the trademark Aldara. In 2009, sales of Aldara were approximately 500 MSEK.
3,75% imiquimod can be used on a larger treatment area, it is once-daily and more tolerable due to the decreased concentration. The patent for this novel imiquimod formulation is pending.
Graceway Pharma is continuing its development program around 3,75% imiquimod. Meda has exclusive rights to follow-up products based on the imiquimod substance.
In consideration for exclusive European rights for 3,75% imiquimod, Meda is expected to pay Graceway Pharma an undisclosed up-front and a single digit royalty on net sales. No milestones payments will be due for 3,75% imiquimod.
Anders Lonner, CEO at Meda, said: “We have very good experience with Aldara in Europe and we look forward to provide AK patients with a new product with improved tolerability that builds on the efficacy of imiquimod.”